ABSTRACT
BACKGROUND: Regional anticoagulation with citrate is the recommended first line treatment for patients receiving continuous renal replacement therapy (CRRT). There is wide variability in filter patency which may be due to differences in patient characteristics and local practice. It is also possible that citrate has effects on primary and secondary haemostasis, fibrinolysis and platelet function that are still unknown. The primary aim of the study is to describe the effect of citrate on coagulation and fibrinolysis pathways in both the patient and the haemodialysis circuit. METHODS: The study will recruit 12 adult patients admitted to the intensive care unit, requiring CRRT with regional citrate anticoagulation for acute kidney injury. Patients with pre-existing thrombotic or bleeding tendencies will be excluded. Thrombin generation, clot lysis and platelet function will be measured at baseline and at 12, 24, 36, 48 and 72 h after commencing CRRT (from the patient and from the circuit). We will describe the evolution of parameters over time as well as the differences in parameters between the patient and the circuit. DISCUSSION: The study will provide new data on the effects of citrate during continuous renal replacement therapy which is not currently available. We will minimise confounding factors through the use of tight exclusion criteria and accept that this will slow down recruitment. Depending on the results, we hope to incorporate the findings into existing clinical guidelines and clinical practice with the aim to prevent premature filter clotting and interruptions in treatment. TRIAL REGISTRATION: The study was registered with clinicaltrials.gov on 10th June 2015 ( NCT02486614 ).
Subject(s)
Acute Kidney Injury/therapy , Anticoagulants/therapeutic use , Blood Coagulation/drug effects , Citric Acid/therapeutic use , Critical Illness/therapy , Renal Replacement Therapy/trends , Acute Kidney Injury/blood , Acute Kidney Injury/diagnosis , Anticoagulants/pharmacology , Blood Coagulation/physiology , Citric Acid/pharmacology , Cohort Studies , Humans , Prospective Studies , Renal Replacement Therapy/adverse effectsABSTRACT
BACKGROUND: Severe hyper- and hyponatraemia is associated with significant risks, yet its correction can also have serious consequences when implemented too fast or inadequately. The safe correction of serum sodium levels is particularly challenging when renal replacement therapy (RRT) is required. METHODS: Using 2 case scenarios, we aim to illustrate a simple method of correcting hyper- and hyponatraemia safely by step-wise manipulation of the dialysate/replacement fluid. RESULTS: During continuous RRT, hypernatraemia can be corrected effectively and safely by adding small pre-calculated amounts of 30% NaCl to the dialysate/replacement fluid bags aiming for a [Na(+)] in the fluid that allows safe equilibration and correction of the serum [Na(+)]. To correct hyponatraemia safely, pre-calculated amounts of sterile water can be added in a step-wise manner to achieve a fluid [Na(+)] that equals the desired target serum [Na(+)]. CONCLUSION: During continuous RRT, the step-wise adjustment of [Na(+)] of dialysate/replacement fluids offers a safe and reliable method to correct sodium disorders.
Subject(s)
Dialysis Solutions/chemistry , Hypernatremia/therapy , Hyponatremia/therapy , Renal Replacement Therapy , Adult , Female , Humans , Male , Middle Aged , Sodium/blood , Water-Electrolyte ImbalanceABSTRACT
Premature circuit clotting is a problem during continuous renal replacement therapy. We describe an algorithm for individualised anticoagulation with unfractionated heparin based on the patient's risk of bleeding and previous circuit life. The algorithm allows effective and safe nurse-led anticoagulation during continuous renal replacement therapy.
Subject(s)
Algorithms , Anticoagulants/administration & dosage , Heparin/administration & dosage , Renal Replacement Therapy/methods , Drug Dosage Calculations , Humans , United KingdomABSTRACT
In patients with acute kidney injury and concomitant severe hyponatraemia or hypernatraemia, rapid correction of the serum Na+ concentration needs to be avoided. The present paper outlines the principles of how to adjust the Na+ concentration in the replacement fluid during continuous renal replacement therapy to prevent rapid changes of the serum Na+ concentration.
